Currently trading on 22.9 x FY - 2014 guidance (of $ 2.125), ICON looks fairly over-valued to me — but with US
big pharma stocks generally back in favour, and the biotech sector on fire, it's no great surprise to see a high valuation here also.
Concerns over these patent expiries, coupled with the recession, caused many investors to flee
Big Pharma stocks altogether.
Not exact matches
Here some of Thurday's
big movers on European
stock markets: Altadis, Imperial Tobacco, Pirelli, Cap Gemini, Swedish Match, Omega
Pharma and AstraZeneca.
DividendMonkey recently posted... Best Dividend
Stock in
Big Pharma, PFE
As a result, biotech and
pharma stocks enjoyed
big gains overall during the first year of the Trump administration.
No. 3: The year of
big pharma In the past five years,
big cap pharmaceutical
stocks have lagged biotech
stocks because they've struggled to fill revenue gaps created by the patent cliff.
DividendMonkey recently posted... Best Dividend
Stock in
Big Pharma, PFE
Generic drug makers may be the «new defensive» plays in modern times, but anyone who has owned either generic drug companies or «
big pharma» drug companies over the last 10 to 12 years can affirm that this defensive
stock stigma is not as true as the classical business models used to indicate.
The Loncar Cancer Immunotherapy ETF (CNCR / Nasdaq) focuses on 30
pharma and biotech
stocks, including
big names like Merck and many you won't recognize.
Laval, Quebec - based Valeant Pharmaceuticals lost almost more than half of its market value ($ 10 billion) since Oct. 21, 2015 when Citron Research, which shorted Valeant's
stock, first publicly alleged that Valeant fraudulently «stuffed the channels,» calling it the «Enron» of
Big Pharma.